Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.

Obesity continues to grab attention at the JP Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

Retatrutide, an experimental drug by Eli Lilly, shows promising results in weight loss by targeting three hormones, ...

Even though some GLP-1 medications like Wegovy and Zepbound are FDA-approved for weight loss, getting insurance companies to ...

Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more ...

Eli Lilly (LLY) has reportedly asked the Biden administration to pause negotiations with drugmakers over pricing, citing ...

A coalition of obesity-related patient advocacy groups is calling on the incoming Trump administration to finalize a proposal ...